- Home
- SGHT vs CATX Comparison
SGHT vs CATX Comparison
Compare SGHT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- CATX
- Stock Information
- Founded
- SGHT 2011
- CATX 1983
- Country
- SGHT United States
- CATX United States
- Employees
- SGHT N/A
- CATX N/A
- Industry
- SGHT Medical Specialities
- CATX Medical/Dental Instruments
- Sector
- SGHT Health Care
- CATX Health Care
- Exchange
- SGHT Nasdaq
- CATX Nasdaq
- Market Cap
- SGHT 140.1M
- CATX 182.9M
- IPO Year
- SGHT 2021
- CATX N/A
- Fundamental
- Price
- SGHT $3.03
- CATX $2.34
- Analyst Decision
- SGHT Buy
- CATX Strong Buy
- Analyst Count
- SGHT 7
- CATX 10
- Target Price
- SGHT $3.92
- CATX $13.89
- AVG Volume (30 Days)
- SGHT 161.2K
- CATX 619.9K
- Earning Date
- SGHT 05-08-2025
- CATX 05-12-2025
- Dividend Yield
- SGHT N/A
- CATX N/A
- EPS Growth
- SGHT N/A
- CATX N/A
- EPS
- SGHT N/A
- CATX N/A
- Revenue
- SGHT $78,109,000.00
- CATX $1,454,000.00
- Revenue This Year
- SGHT N/A
- CATX N/A
- Revenue Next Year
- SGHT $11.17
- CATX N/A
- P/E Ratio
- SGHT N/A
- CATX N/A
- Revenue Growth
- SGHT N/A
- CATX 1.40
- 52 Week Low
- SGHT $2.03
- CATX $1.60
- 52 Week High
- SGHT $8.45
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- SGHT 56.13
- CATX 51.17
- Support Level
- SGHT $2.81
- CATX $2.18
- Resistance Level
- SGHT $3.26
- CATX $2.65
- Average True Range (ATR)
- SGHT 0.24
- CATX 0.16
- MACD
- SGHT -0.01
- CATX 0.02
- Stochastic Oscillator
- SGHT 38.57
- CATX 56.25
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.